• Wondering if JBS at around US$17.34 actually offers value or if the easy gains are gone? This breakdown will help you weigh what the current price might really reflect.
• The stock has delivered a 15.1% return over the last 7 days, 2.7% over the past 30 days, and 22.3% year to date, which has likely sharpened attention on both its potential and its risks.
• Recent coverage has focused on JBS as a major player in the global food and meat supply chain, with attention on topics such as industry pricing conditions, input cost pressures, and regulatory oversight. This context helps explain why investors are reassessing how much they are willing to pay for its shares right now.
• JBS currently has a valuation score of 5 out of 6. The next sections will walk through what that means across different valuation methods and then finish with a way to think about valuation that goes beyond any single model.

Approach 1: JBS Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth today by projecting its future cash flows and then discounting those back to a single present value figure.

For JBS, the model uses a 2 Stage Free Cash Flow to Equity approach, based on cash flows in US$. The latest twelve month free cash flow sits at about $1.07b. Analyst estimates and subsequent extrapolations see free cash flow figures in the low to mid billions each year out to 2035, with the 2035 projection at roughly $4.13b. Simply Wall St uses direct analyst forecasts where available, then extends those projections for later years.

When these projected cash flows are discounted back, the model arrives at an estimated intrinsic value of US$73.89 per share. Against a share price around US$17.34, this indicates the stock is 76.5% undervalued under this specific DCF framework.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests JBS is undervalued by 76.5%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Approach 2: JBS Price vs Earnings

For a profitable company like JBS, the P/E ratio is a useful cross check because it links what you pay for each share directly to the earnings that back it.

What counts as a "normal" P/E often reflects how the market views a company’s growth potential and risk. Higher expected growth or lower perceived risk can support a higher multiple, while slower growth or higher risk usually line up with a lower one.

JBS currently trades on a P/E of 9.17x. That sits well below the Food industry average of about 20.02x and also below the broader peer group average of 41.34x. Simply Wall St’s Fair Ratio for JBS is 19.03x, which is its own estimate of what a balanced P/E could look like for this company.

The Fair Ratio is designed to be more tailored than a simple industry or peer comparison because it factors in elements such as earnings growth, profit margins, risk profile, industry, and market cap, rather than assuming every company should share the same benchmark.

Comparing JBS’s current P/E of 9.17x with the Fair Ratio of 19.03x points to the shares trading below that Fair Ratio estimate.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your JBS Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives on Simply Wall St’s Community page let you turn your view of JBS into a clear story that links what you think about its business, future revenue, earnings and margins to a forecast and Fair Value, then compares that Fair Value with today’s price to help you judge if JBS suits your own buy or sell criteria, all while updating automatically as new news or earnings arrive so that, for example, one investor might build an optimistic JBS Narrative closer to the US$26.07 analyst target and another a more cautious one near US$16.47, both using the same company data but different assumptions about how its multi protein business and margins could play out.

Do you think there's more to the story for JBS? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.